








Pink Seminar

Nicolas Le Novère, EMBL-EBI

Computational Neurobiology



Computational Systems Biology



A common layout for the Tower of Babel: The Systems Biology Graphical Notation

(on the behalf of SBGN editors, authors and contributors)







Figure 4. Contribution of copy number-induced gene expression differences to the SCLC and NSCLC phenotypes. Principal component analysis was performed using all 243 Affymetrix probe sets demonstrating expression differences as a result of copy number alterations. The SCLC samples are indicated by solid circles, while the NSCLC samples are indicated by open circles. Strong separation of the SCLC and NSCLC cell lines along principal component 1 demonstrates the contribution of these genes to the differential phenotypes.

amplification in the NSCLC samples as well suggests that this gene may play an essential role in the development of lung cancers (Garnis et al. 2006).

It is noteworthy that a subset of the genomic similarities between the SCLC and NSCLC cell lines could be the result of adaptation to culturing conditions. Owing to this, the greatest insight into the biology of the clinical disease will be attainable through analysis of differences (rather than their similarities) in genomic alterations and gene regulation.

Regions of difference



Through our analysis, numerous regions throughout the genome were determined to be differentially altered between the SCLC and NSCLC samples. This difference-based approach compensates for random cell culturing artifacts and should identify the regions most strongly linked to clinical disease. These regions ranged in size from whole chromosomes (chromosome 21) to discrete peaks, kilobases in size (kb). Using our stringent, multi-step criteria (Fisher's exact test followed by additional thresholding), we detected several regions that differed strongly in their alteration status between the cell types; we refer to these as phenotype-specific copy number alterations (PSCNAs). These included 1p36.33-1p34.2,




© 2006 Cancer Research UK

SCLC-specific oncogenic target
NSCLC-specific oncogenic target
NSCLC-specific tumour suppressor target
Critical node validated by RT-PCR

compartment



$X \longrightarrow Y$



is transformed into

translocates (X "=" Y)

is degraded into

associates into

dissociates into

stimulates the activity of

stimulates the expression of

catalyses the formation of

$X \longrightarrow Y$

X inhibits Y

is transformed into

translocates (X "=" Y)

is degraded into


associates into

dissociates into

stimulates the activity of

stimulates the expression of

catalyses the formation of



is transformed into

translocates ($X \rightleftharpoons Y$)

is degraded into

associates into


dissociates into

stimulates the activity of


stimulates the expression of


catalyses the formation of

X inhibits Y



Can this be understood by biologists?







- Is degraded?



Associates into?


Translocates?


No idea. Reciprocal stimulation?

Every computer scientist understands those










What did those diagrams bring?



Basic science

Systems of Life

Systems Biology



Technology



EXTREME GENETIC ENGINEERING

An Introduction to Synthetic Biology


January 2007



What happens if one cannot read the blueprint





What happens if one cannot read the blueprint



Why can-we understand electric diagrams?

- Standard symbols
 - Simple shapes, easily recognisable
 - Limited number of basic symbols (<70)
 - Similarity of shapes reflects similarity of functions
- Unambiguous interpretation of the circuits
- Endorsed by the community for practical reasons
 - End-users: manufacturers
 - Tool developers
 - Publishing industry
 - Teaching communities



- Kurt W Kohn (1998) *Oncogene*, 16: 1065-1075
- Kurt W. Kohn (1999) *Mol Biol Cell*, 10(8):2703-2734




Figure 6A: The Cyclin - E2F cell cycle control system (version 3a - June 8, 1999)

MIM: 6282

State node symbols

Protein	
Receptor	
Ion channel (closed)	
Ion channel (open)	
Truncated protein	
Gene	
RNA	
Anti-sense RNA	
Ion	
Simple molecule	
Unknown	
Phenotype	
Homodimer / N-mer with N stacked symbols	
Active protein	

Arc symbols (Transit node and edges)

State transition	
Known transition omitted	
Unknown transition	
Bidirectional transition	
Translocation	
Association	
Dissociation	
Truncation	
Promote transition	
Inhibit transition	
Add reactant	
Add product	
AND	
OR	

Reduced notation symbols

Category-I reduced notation

Degradation	
Transcription	
Translation	
Module	

Category-II reduced notation (viewer only)


Activation/inhibition/modification	
------------------------------------	--

Node structure

Residue modification	
Complex state node	
Promotor and coding structure for gene	
Exon structure for RNA	

- Kitano (2003)
Biosilico, 1: 169-170
- Kitano et al (2005)
Nat Biotech, 23: 961-966

Cell Cycle in Kitano's Process Diagram



- Somehow fuzzy semantics
 - No structured data model or ontology behind the notation
 - Overlapping concepts rather than sub-classing
 - Gaps in the coverage of biochemistry or modelling
 - Ambiguous interpretation of the graph
- Little software support (except CellDesigner for Kitano's Process Diagrams)
- No community involvement
 - No systematic bug tracking and consistency checking
 - No comprehensive coverage (focussed on some use-cases)
 - No endorsement by the tool developers or by the end-users

Enters The Systems Biology Graphical Notation



<http://www.sbgn.org/>

- An unambiguous way of graphically describing and interpreting biochemical and cellular events
- Limited amount of symbols
Re-use existing symbols
- ☞ Smooth learning curve
- Can represent logical or mechanistic models, biochemical pathways, at different levels of granularity
- Detailed technical specification, precise data-models and growing software support
- Initiated by Hiroaki Kitano. Developed over four years by a diverse community


The Systems Biology Graphical Notation

Nicolas Le Novère¹, Michael Hucka², Huaiyu Mi³, Stuart Moodie⁴, Falk Schreiber^{5,6}, Anatoly Sorokin⁷, Emek Demir⁸, Katja Wegner⁹, Mirit I Aladjem¹⁰, Sarala M Wimalaratne¹¹, Frank T Bergman¹², Ralph Gauges¹³, Peter Ghazal^{4,14}, Hideya Kawaji¹⁵, Lu Li¹, Yukiko Matsuoka¹⁶, Alice Villéger^{17,18}, Sarah E Boyd¹⁹, Laurence Calzone²⁰, Melanie Courtot²¹, Ugur Dogrusoz²², Tom C Freeman^{14,23}, Akira Funahashi²⁴, Samik Ghosh¹⁶, Akiya Jouraku²⁴, Sohyoung Kim¹⁰, Fedor Kolpakov^{25,26}, Augustin Luna¹⁰, Sven Sahle¹³, Esther Schmidt¹, Steven Watterson^{4,22}, Guanming Wu²⁷, Igor Goryanin⁴, Douglas B Kell^{18,28}, Chris Sander⁸, Herbert Sauro¹², Jacky L Snoep²⁹, Kurt Kohn¹⁰ & Hiroaki Kitano^{16,30,31}

¹EMBL European Bioinformatics Institute, Hinxton, UK. ²Engineering and Applied Science, California Institute of Technology, Pasadena, California, USA. ³SRI International, Menlo Park, California, USA. ⁴Centre for Systems Biology at Edinburgh, University of Edinburgh, Edinburgh, UK. ⁵Leibniz Institute of Plant Genetics and Crop Plant Research, Gatersleben, Germany. ⁶Institute of Computer Science, University of Halle, Halle, Germany. ⁷School of Informatics, University of Edinburgh, Edinburgh, UK. ⁸Memorial Sloan Kettering Cancer Center - Computational Biology Center, New York, NY, USA. ⁹Science and Technology Research Institute, University of Hertfordshire, Hatfield, UK. ¹⁰National Cancer Institute, Bethesda, Maryland, USA. ¹¹Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand. ¹²Department of Bioengineering, University of Washington, Seattle, Washington, USA. ¹³BIOQUANT, University of Heidelberg, Heidelberg, Germany. ¹⁴Division of Pathway Medicine, University of Edinburgh Medical School, Edinburgh, UK. ¹⁵Riken OMICS Science Center, Yokohama City, Kanagawa, Japan. ¹⁶The Systems Biology Institute, Tokyo, Japan. ¹⁷School of Computer Science, University of Manchester, Manchester, UK. ¹⁸Manchester Interdisciplinary Biocentre, Manchester, UK. ¹⁹Clayton School of Information Technology, Faculty of Information Technology, Monash University, Melbourne, Victoria, Australia. ²⁰U900 INSERM, Paris Mines Tech, Institut Curie, Paris, France. ²¹Terry Fox Laboratory, British Columbia Cancer Research Center, Vancouver, British Columbia, Canada. ²²Bilkent Center for Bioinformatics, Bilkent University, Ankara, Turkey. ²³The Roslin Institute, University of Edinburgh, Midlothian, UK. ²⁴Department of Biosciences and Informatics, Keio University, Hiyoshi, Kouhoku-ku, Yokohama, Japan. ²⁵Institute of Systems Biology, Novosibirsk, Russia. ²⁶Design Technological Institute of Digital Techniques SB RAS, Novosibirsk, Russia. ²⁷Ontario Institute for Cancer Research, Toronto, Ontario, Canada. ²⁸School of Chemistry, University of Manchester, Manchester, UK. ²⁹Department of Biochemistry, Stellenbosch University, Matieland, South Africa. ³⁰Sony Computer Science Laboratories, Tokyo, Japan. ³¹Okinawa Institute of Science and Technology, Okinawa, Japan. Correspondence should be addressed to N.L.N. (lenov@ebi.ac.uk).

39 authors, 31 affiliations


Activity Flows



- Ambiguous
- Conceptual
- Sequential


Graph trinity: three languages in one notation

Process Descriptions




- Unambiguous
- Mechanistic
- Sequential
- Combinatorial explosion

Entity Relationships




- Unambiguous
- Mechanistic
- Non-sequential
- Independence of relationships

Activity Flows





- Ambiguous
- Conceptual
- Sequential


Three orthogonal projections of biology





Process Descriptions are bipartite graphs





















<i>Arc\EPN</i>	<i>macromolecule</i>	<i>simple chemical</i>	<i>unspecified entity</i>	<i>multimer</i>	<i>complex</i>	<i>nucleic acid feature</i>	<i>tag</i>	<i>source/sink</i>	<i>perturbation</i>	<i>observable</i>	<i>submap</i>
<i>consumption</i>	I	I	I	I	I	I		I			
<i>production</i>	O	O	O	O	O	O		O			
<i>modulation</i>	I	I	I	I	I	I			I	O	
<i>stimulation</i>	I	I	I	I	I	I			I	O	
<i>catalysis</i>	I	I	I	I	I				I	O	
<i>inhibition</i>	I	I	I	I	I	I			I	O	
<i>trigger</i>	I	I	I	I	I	I			I	O	
<i>logic arc</i>	I	I	I	I	I	I					
<i>equivalence arc</i>	I	I	I	I	I	I	O				O


<i>Arc\PN</i>	<i>transition</i>	<i>omitted process</i>	<i>uncertain process</i>	<i>association</i>	<i>dissociation</i>	<i>and</i>	<i>or</i>	<i>not</i>
<i>consumption</i>	O	O	O	O	O(1)			
<i>production</i>	I	I	I	I(1)	I			
<i>modulation</i>	O	O	O			I(1)	I(1)	I(1)
<i>stimulation</i>	O	O	O			I(1)	I(1)	I(1)
<i>catalysis</i>	O	O	O			I(1)	I(1)	I(1)
<i>inhibition</i>	O	O	O			I(1)	I(1)	I(1)
<i>trigger</i>	O	O	O			I(1)	I(1)	I(1)
<i>logic arc</i>						O	O	O(1)
<i>equivalence arc</i>								





















catalytic processes


transport processes

contractile proteins




- Generics, i.e, entity pools representing several possible biochemical types. (e.g. MAPK instead of ERK1 and ERK2).
- Trans-compartment (e.g. transmembrane) structures
- Logical combination of state-variable values (and close-world/open-world position)
- Moving and transforming compartments
- Non-chemical entity pool nodes (“voltage”, “pH” ...)

Entity Relationships can be viewed as rules




Entity Relationships can be viewed as rules



If **A exists**, the **assignment** of the value **P** to the **state variable T** of **B** is **increased**


Entity Relationships can be viewed as rules



If **A** exists, the assignment of the value **P** to the state variable **T** of **B** is increased


(**A** stimulates the phosphorylation of **B** on the threonine)

Entity Relationships can be viewed as rules



If **A exists**, the **assignment of the value P** to the **state variable T of B** is **increased**

If **P is assigned to the state variable T of B**, the **assignment of the value P** to the **state variable S of C** is **decreased**










Process Diagram:
 “once a state variable value,
 always a state variable value”

$2^{12} = 4096$ states
 (i.e. EPN glyphs) for EGFR
 and 4096 complexes between
 EGFR and targets








Entity Nodes

Relationship Nodes



Entity Nodes








Relationship Nodes



continuants,
things that exists (or not)

Entity Nodes

Relationship Nodes



occurents,
events that may happen (or not)

symbols \ Arc	<i>assignment</i>	<i>interaction</i>	<i>modulation</i>	<i>stimulation</i>	<i>inhibition</i>	<i>necessary stimulation</i>	<i>absolute stimulation</i>	<i>absolute inhibition</i>	<i>logic arc</i>
<i>entity</i>		IO	I	I	I	I	I	I	I
<i>outcome</i>		I(1)O(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)
<i>and</i>			I(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)O
<i>or</i>			I(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)O
<i>not</i>			I(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)O(1)
<i>delay</i>			I(1)	I(1)	I(1)	I(1)	I(1)	I(1)	I(1)O(1)
<i>perturbing agent</i>			I	I	I	I	I	I	I
<i>unit of information</i>		IO							
<i>state variable</i>	I(1)O(1)								
<i>modulation</i>				O	O	O	O	O	
<i>stimulation</i>				O	O	O	O	O	
<i>inhibition</i>				O	O	O	O	O	
<i>necessary stimulation</i>				O	O	O	O	O	
<i>absolute stimulation</i>				O	O	O	O	O	
<i>absolute inhibition</i>				O	O	O	O	O	
<i>assignment</i>				O	O	O	O	O	
<i>interaction</i>				O	O	O	O	O	
<i>phenotype</i>				O	O	O	O	O	

3.4.2 Influences

A *modulation* (Section 2.4.3.1) linking an *entity node* E and a relationship R means: “If E exists then R is either reinforced or weakened”.


A *stimulation* (Section 2.4.3.2) linking an *entity node* E and a relationship R means: “If E exists then R is reinforced” or “If E exists then the probability of R is increased”.


An *absolute stimulation* (Section 2.4.3.6) linking an *entity node* E and a relationship R means: “If E exists then R always takes place”.

A *necessary stimulation* (Section 2.4.3.4) linking an *entity node* E and a relationship R means: “ R only takes place if E exists”.

An *inhibition* (Section 2.4.3.3) linking an *entity node* E and a relationship R means: “If E exists then R is weakened” or “If E exists then the probability of R is lowered”.


An *absolute inhibition* (Section 2.4.3.5) linking an *entity node* E and a relationship R means: “If E exists then R never takes place”.






- Internal structure of entities, such as domains, sites, features. (NB: This has been agreed upon for the next version. We will be able to “nest” entities)
- Identification of instances: How to differentiate between several instances of the same entity, differentially involved in a relationships (e.g. trans-phosphorylation)?
- Identification of generics: How to lump together several entities for a given relationships? (e.g. MAPK instead of ERK1 and ERK2).


Activity nodes




Modulating Arcs



Auxiliary Units




Logical Operators





Container Nodes





Example of Activity Flow map














Linking SBGN maps to external information



Linking SBGN maps to external information

EMBL-EBI ChEBI database search results for **calcium(2+)** (CHEBI:29108).

Search ChEBI:

ChEBI Name: **calcium(2+)**
 ChEBI ID: **CHEBI:29108**
 Last Modified: 10 March 2008

Options: ☒ Image ☐ Applet

Links: [Molfile](#), [InChI](#), [InChIKey](#), [SMILES](#)

Additional information: InChI=1/Ca/q+2, InChIKey=BHPQYMZQTOCNFJ-UHFFFAOYAP, [Ca++]



<http://www.ebi.ac.uk/miriam/>

Le Novère et al (2005)
Nat Biotechnol, 23: 1509-1515.

[BioModels Home](#)
[Browse models](#)
[Submit](#)
[Sign in](#)
[Support](#)
[About BioModels](#)
[Search](#)

BIOModel0000000005 - Tyson1991_CellCycle_svar

[SBML](#) | Other formats | View GF Reaction Graph | [Submit Model Comment/bug](#)

[Model](#) | [Overview](#) | [Math](#) | [Physical entities](#) | [Parameters](#)

[Reference Publication](#)

Publication: [131272](#)

Proc Natl Acad Sci U S A 1991 Aug 8(16): 7328-32.
 Modeling the cell division cycle: cdc2 and cyclin interactions.
 Tyson JL
 Department of

<http://www.ebi.ac.uk - BioModels Database - SeaMonk>

BIOModel0000000005 Tyson1991
<http://www.ebi.ac.uk - BioModels Database - SeaMonk>

Original Model: Unspecified

Submitter: [Nicolas Le Novre](#)

Submission Date: 2005-09-13T12:31:09+00:00

Last Modification Date: 2009-02-25T14:58:48+00:00

Creation Date: 2005-02-08T18:28:27+00:00

Creator: [Bruce Shapiro](#)
[View/submit history](#)

Curation Results:









Cell Cycle Model: Tyson (1991, 6 variables)

Description
 A model of the cell cycle based on the interactions between P-cyclin-cdc2-P complex, M (active MPF, P-cyclin-cdc2 complex)

```

    graph TD
      total_cdc2((total cdc2)) --> p_cyclin_cdc2_p((p-cyclin cdc2-p))
      p_cyclin_cdc2_p --> p_cyclin((p-cyclin))
      p_cyclin --> cdc2k((cdc2k))
      cdc2k --> cdc2k_P((cdc2k-P))
      cdc2k_P --> cyclin((cyclin))
      cyclin --> p_cyclin_cdc2_p
      p_cyclin_cdc2_p --> cdc2k
      cdc2k --> p_cyclin_cdc2_p
      cdc2k_P --> p_cyclin_cdc2_p
      cyclin --> p_cyclin_cdc2_p
      p_cyclin_cdc2_p --> p_cyclin
      p_cyclin --> cdc2k
      cdc2k --> cdc2k_P
      cdc2k_P --> cyclin
      cyclin --> p_cyclin_cdc2_p
    
```

Done




- SBGN Process Descriptions
 - Level 1 Version 1.0 released on August 23rd 2008
 - Level 1 Version 1.1 released on September 1st 2009
 - Level 1 Version 2 under discussion
- SBGN Entity Relationships
 - Level 1 Version 1.0 released on September 1st 2009
- SBGN Activity Flows
 - Level 1 Version 1.0 released on September 1st 2009

- 4rd SBGN hackathon (SBGN 5.5)
 - 21-23 April 2010
 - Wittenberg
- 6th SBGN forum (provisional)
 - October 2010
 - Edinburgh
 - Satellite of ICSB 2010



- Future hackathons and forums
 - part of HARMONY and COMBINE meetings
 - SBML (model), SED-ML (simulation), SBO (semantics), MIRIAM (metadata), SBGN (graphical), BioModels DB (distribution), ?



A Visual Notation for Network Diagrams in Biology

SBGN.org is the global portal for documentation, news, and other information about the Systems Biology Graphical Notation (SBGN) project, an effort to standardize the graphical notation used in maps of biochemical and cellular processes studied in systems biology.

Standardizing the visual representation is crucial for more efficient and accurate transmission of biological knowledge between different communities in research, education, publishing, and more. When biologists are as familiar with the notation as electronics engineers are familiar with the notation of circuit schematics, they can save the time and effort required to familiarize themselves with different notations, and instead spend more time thinking about the biology being depicted.

SBGN is made up of [[1 three orthogonal languages](#)], representing different visions of biological systems. Each language defines a comprehensive set of symbols with precise semantics, together with detailed syntactic rules how maps are to be interpreted.

On this site, you can browse some [example maps](#) to get a feeling for SBGN, read the SBGN [specification documents](#), join [online discussions](#), see current working documents and software support in the [SBGN wiki](#), and much more.


SBGN is the work of many people. It would not have been possible without the generous [support of multiple organizations](#) over the years, for which we are very thankful.

To quote SBGN as a whole, please use:

Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E, Wegner K, Aladjem MI, Wimalaratne SM, Bergman FT, Gauges R, Ghazal P, Kawaji H, Li L, Matsuoka Y, Villéger A, Boyd SE, Calzone L, Courtot M, Dogrusoz U, Freeman TC, Funahashi A, Ghosh S, Jouraku A, Kim S, Kolpakov F, Luna A, Sahle S, Schmidt E, Watterson S, Wu G, Goryanin I, Kell DB, Sander C, Sauro H, Snoep JL, Kohn K, Kitano H. The Systems Biology Graphical Notation. [Nat Biotechnol. 2009 27\(8\):735-41.](#)

SBGN News
(02 Sep '09) The first specifications for [SBGN Entity Relationships](#) and [SBGN Activity Flows](#) are out.

What happens if one can read the blueprint



SBGN editors

- Nicolas Le Novère (UK)
- Stuart Moodie (UK)
- Anatoly Sorokin (UK)
- Michael Hucka (US)
- Falk Schreiber (DE)
- Huaiyu Mi (US)

Special contributors

Emek Demir, Katja Wegner, Mirit Aladjem, Sarala Wimalaratne, Frank Bergman, Ralph Gauges, Peter Ghazal, Kawaji Hideya, Lu Li, Yukiko Matsuoka, Alice Villéger, Sarah Boyd, Laurence Calzone, Melanie Courtot, Ugur Dogrusoz, Akira Funahashi, Sohyoung Kim, Fedor Kolpakov, Augustin Luna, Sven Sahle, Douglas Kell, Kurt Kohn, Hiroaki Kitano

The whole community participating to SBGN meetings, and mailing-lists

